Dr. Martens plc (LON:DOCS - Get Free Report) was up 24% during trading on Thursday . The company traded as high as GBX 76.40 ($1.04) and last traded at GBX 74.35 ($1.01). Approximately 7,443,822 shares were traded during trading, an increase of 232% from the average daily volume of 2,245,163 shares. The stock had previously closed at GBX 59.95 ($0.81).
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada lowered their price target on shares of Dr. Martens from GBX 7,000 ($95.06) to GBX 6,000 ($81.48) and set a "sector perform" rating on the stock in a report on Monday, May 19th.
Get Our Latest Analysis on DOCS
Dr. Martens Stock Performance
The company has a market cap of £731.96 million, a PE ratio of 10.69, a PEG ratio of 6.40 and a beta of 0.11. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The business's 50 day moving average is GBX 54.73 and its two-hundred day moving average is GBX 62.64.
Dr. Martens (LON:DOCS - Get Free Report) last posted its quarterly earnings results on Thursday, June 5th. The company reported GBX 2.40 ($0.03) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities research analysts anticipate that Dr. Martens plc will post 2.5809394 EPS for the current year.
Dr. Martens Cuts Dividend
The firm also recently announced a dividend, which was paid on Tuesday, April 8th. Investors of record on Thursday, March 6th were paid a dividend of GBX 0.85 ($0.01) per share. This represents a yield of 1.47%. The ex-dividend date was Thursday, March 6th. Dr. Martens's dividend payout ratio (DPR) is presently 42.53%.
Insider Buying and Selling
In related news, insider Giles Wilson bought 32,640 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was bought at an average cost of GBX 54 ($0.73) per share, with a total value of £17,625.60 ($23,934.82). In the last three months, insiders have acquired 33,206 shares of company stock valued at $1,792,771. Corporate insiders own 4.36% of the company's stock.
About Dr. Martens
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Stories
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
